COVID-19 in Solid Organ Transplant Recipients in Spain Throughout 2020: Catching the Wave?
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
01 10 2021
01 10 2021
Historique:
pubmed:
10
7
2021
medline:
12
10
2021
entrez:
9
7
2021
Statut:
ppublish
Résumé
Few studies have analyzed differences in clinical presentation and outcomes in solid organ transplant (SOT) recipients with coronavirus disease 2019 (COVID-19) across different pandemic waves. In this multicenter, nationwide, prospective study, we compared demographics and clinical features, therapeutic management, and outcomes in SOT recipients diagnosed with COVID-19 in Spain before (first wave) or after (second wave) 13 July 2020. Of 1634 SOT recipients, 690 (42.2%) and 944 (57.8%) were diagnosed during the first and second periods, respectively. Compared with the first wave, recipients in the second were younger (median: 63 y [interquartile range, IQR: 53-71] versus 59 y [IQR: 49-68]; P < 0.001) and less likely to receive anti-severe acute respiratory syndrome coronavirus 2 drugs (81.8% versus 8.1%; P < 0.001), with no differences in immunomodulatory therapies (46.8% versus 47.0%; P = 0.931). Adjustment of immunosuppression was less common during the second period (76.4% versus 53.6%; P < 0.001). Hospital admission (86.7% versus 58.1%; P < 0.001), occurrence of acute respiratory distress syndrome (34.1% versus 21.0%; P < 0.001), and case-fatality rate (25.8% versus 16.7%; P < 0.001) were lower in the second period. In multivariate analysis, acquiring COVID-19 during the first wave was associated with an increased risk of death (OR: 1.47; 95% confidence interval [CI], 1.12-1.93; P = 0.005), although this impact was lost in the subgroup of patients requiring hospital (OR: 0.97; 95% CI, 0.73-1.29; P = 0.873) or intensive care unit admission (OR: 0.65; 95% CI, 0.35-1.18; P = 0.157). We observed meaningful changes in demographics, therapeutic approaches, level of care, and outcomes between the first and second pandemic waves. However, outcomes have not improved in the more severe cases of posttransplant COVID-19.
Sections du résumé
BACKGROUND
Few studies have analyzed differences in clinical presentation and outcomes in solid organ transplant (SOT) recipients with coronavirus disease 2019 (COVID-19) across different pandemic waves.
METHODS
In this multicenter, nationwide, prospective study, we compared demographics and clinical features, therapeutic management, and outcomes in SOT recipients diagnosed with COVID-19 in Spain before (first wave) or after (second wave) 13 July 2020.
RESULTS
Of 1634 SOT recipients, 690 (42.2%) and 944 (57.8%) were diagnosed during the first and second periods, respectively. Compared with the first wave, recipients in the second were younger (median: 63 y [interquartile range, IQR: 53-71] versus 59 y [IQR: 49-68]; P < 0.001) and less likely to receive anti-severe acute respiratory syndrome coronavirus 2 drugs (81.8% versus 8.1%; P < 0.001), with no differences in immunomodulatory therapies (46.8% versus 47.0%; P = 0.931). Adjustment of immunosuppression was less common during the second period (76.4% versus 53.6%; P < 0.001). Hospital admission (86.7% versus 58.1%; P < 0.001), occurrence of acute respiratory distress syndrome (34.1% versus 21.0%; P < 0.001), and case-fatality rate (25.8% versus 16.7%; P < 0.001) were lower in the second period. In multivariate analysis, acquiring COVID-19 during the first wave was associated with an increased risk of death (OR: 1.47; 95% confidence interval [CI], 1.12-1.93; P = 0.005), although this impact was lost in the subgroup of patients requiring hospital (OR: 0.97; 95% CI, 0.73-1.29; P = 0.873) or intensive care unit admission (OR: 0.65; 95% CI, 0.35-1.18; P = 0.157).
CONCLUSIONS
We observed meaningful changes in demographics, therapeutic approaches, level of care, and outcomes between the first and second pandemic waves. However, outcomes have not improved in the more severe cases of posttransplant COVID-19.
Identifiants
pubmed: 34241988
pii: 00007890-202110000-00010
doi: 10.1097/TP.0000000000003873
pmc: PMC8487705
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2146-2155Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Domínguez-Gil B, Coll E, Fernández-Ruiz M, et al. COVID-19 in Spain: transplantation in the midst of the pandemic. Am J Transplant. 2020;20:2593–2598.
Loupy A, Aubert O, Reese PP, et al. Organ procurement and transplantation during the COVID-19 pandemic. Lancet. 2020;395:e95–e96.
Global Observatory Donation and Transplantation. WHO-ONT. Available at http://www.transplant-observatory.org/ . Accessed June 2021.
Ministry of Health. Actualización n° 363. Enfermedad por el coronavirus (COVID-19 ). Available at https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/Actualizacion_363_COVID-19.pdf . Accessed June 2021.
Fan G, Yang Z, Lin Q, et al. Decreased case fatality rate of COVID-19 in the second wave: a study in 53 countries or regions. Transbound Emerg Dis. 2021;68:213–215.
Carlos III Health Institute. Informes COVID-19. Available at https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Paginas/InformesCOVID-19.aspx . Accessed June 2021.
Raja MA, Mendoza MA, Villavicencio A, et al. COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis of current literature. Transplant Rev (Orlando). 2021;35:100588.
Mahalingasivam V, Craik A, Tomlinson LA, et al. A systematic review of COVID-19 and kidney transplantation. Kidney Int Rep. 2021;6:24–45.
Coll E, Fernández-Ruiz M, Sánchez-Álvarez JE, et al.; Spanish Group for the Study of COVID-19 in Transplant Recipients. COVID-19 in transplant recipients: the Spanish experience. Am J Transplant. 2021;21:1825–1837.
Linares L, Cofan F, Diekmann F, et al.; Hospital Clínic COVID-19 research group. A propensity score-matched analysis of mortality in solid organ transplant patients with COVID-19 compared to non-solid organ transplant patients. PLoS One. 2021;16:e0247251.
Chavarot N, Gueguen J, Bonnet G, et al.; Critical COVID-19 France Investigators. COVID-19 severity in kidney transplant recipients is similar to nontransplant patients with similar comorbidities. Am J Transplant. 2021;21:1285–1294.
Hadi YB, Naqvi SFZ, Kupec JT, et al. Outcomes of COVID-19 in solid organ transplant recipients: a propensity-matched analysis of a large research network. Transplantation. 2021;105:1365–1371.
Domínguez-Gil B, Fernández-Ruiz M, Hernández D, et al. Organ donation and transplantation during the COVID-19 pandemic: a summary of the Spanish experience. Transplantation. 2021;105:29–36.
Ison MG, Hager J, Blumberg E, et al. Donor-derived disease transmission events in the United States: data reviewed by the OPTN/UNOS Disease Transmission Advisory Committee. Am J Transplant. 2009;9:1929–1935.
Ranieri VM, Rubenfeld GD, Thompson BT, et al.; ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307:2526–2533.
Villanego F, Mazuecos A, Pérez-Flores IM, et al. Predictors of severe COVID-19 in kidney transplant recipients in the different epidemic waves: analysis of the Spanish Registry. Am J Transplant. 2021;21:2573–2582.
Kaul DR, Valesano AL, Petrie JG, et al. Donor to recipient transmission of SARS-CoV-2 by lung transplantation despite negative donor upper respiratory tract testing. Am J Transplant. 2021; 21:2885–2889.
RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396:1345–1352.
Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19. N Engl J Med. 2020;383:517–525.
Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med. 2020;382:2411–2418.
Beigel JH, Tomashek KM, Dodd LE. Remdesivir for the treatment of COVID-19 – preliminary report. Reply. N Engl J Med. 2020;383:994.
MINISTERIO DE SANIDAD. Protocolo farmacoclínico del uso de Remdesivir (veklury®) en el tratamiento de la enfermedad por covid-19 en el Sistema Nacional de Salud. Available at https://www.mscbs.gob.es/profesionales/farmacia/valtermed/docs/20200908_Protocolo_farmacoclinico_remdesivir2.pdf . Accessed June 2021.
Horby P, Lim WS, Emberson JR, et al.; RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384:693–704.
Gordon AC, Mouncey PR, Al-Beidh F, et al.; REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with COVID-19. N Engl J Med. 2021;384:1491–1502.
Fernández-Ruiz M, López-Medrano F, Aguado JM. Tocilizumab for the treatment of COVID-19. Expert Opin Biol Ther. 2021;21:431–434.
Trujillo H, Caravaca-Fontán F, Sevillano Á, et al. Tocilizumab use in kidney transplant patients with COVID-19. Clin Transplant. 2020;34:e14072.
Pérez-Sáez MJ, Blasco M, Redondo-Pachón D, et al.; Spanish Society of Nephrology COVID-19 Group. Use of tocilizumab in kidney transplant recipients with COVID-19. Am J Transplant. 2020;20:3182–3190.
Fernández-Ruiz M, Aguado JM. Immunomodulatory therapies for COVID-19 in solid organ transplant recipients. Curr Transplant Rep. 2020;7:379–389.
Avery RK. COVID-19 therapeutics for solid organ transplant recipients; 6 months into the pandemic: where are we now? Transplantation. 2021;105:56–60.
Colmenero J, Rodríguez-Perálvarez M, Salcedo M, et al. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. J Hepatol. 2021;74:148–155.
Karruli A, Spiezia S, Boccia F, et al. Effect of immunosuppression maintenance in solid organ transplant recipients with COVID-19: systematic review and meta-analysis. Transpl Infect Dis. 2021:e13595. doi:10.1111/tid.13595
doi: 10.1111/tid.13595
Actualización 6. Estrategia de vacunación frente a COVID-19 en España. Available at https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/COVID-19_Actualizacion6_EstrategiaVacunacion.pdf . Accessed June 2021.
Semicyuc.org. Recomendaciones éticas para la toma de decisiones en la situación excepcional de crisis por pandemia COVID-19 en las unidades de cuidados intensivos. Available at https://semicyuc.org/wp-content/uploads/2020/03/%C3%89tica_SEMICYUC-COVID-19.pdf . Accessed June 2021.
Kates OS, Haydel BM, Florman SS, et al. COVID-19 in solid organ transplant: a multi-center cohort study. Clin Infect Dis. 2020:ciaa1097. doi:10.1093/cid/ciaa1097
doi: 10.1093/cid/ciaa1097
Belli LS, Fondevila C, Cortesi PA, et al.; ELITA-ELTR COVID-19 Registry. Protective role of tacrolimus, deleterious role of age and comorbidities in liver transplant recipients with COVID-19: results from the ELITA/ELTR Multi-center European Study. Gastroenterology. 2021;160:1151–1163.e3.